MX361499B - Baricitinib deuterado. - Google Patents

Baricitinib deuterado.

Info

Publication number
MX361499B
MX361499B MX2015002040A MX2015002040A MX361499B MX 361499 B MX361499 B MX 361499B MX 2015002040 A MX2015002040 A MX 2015002040A MX 2015002040 A MX2015002040 A MX 2015002040A MX 361499 B MX361499 B MX 361499B
Authority
MX
Mexico
Prior art keywords
baricitinib
deuterated
formula
compound
pharmaceutically acceptable
Prior art date
Application number
MX2015002040A
Other languages
English (en)
Other versions
MX2015002040A (es
Inventor
Roger D Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of MX2015002040A publication Critical patent/MX2015002040A/es
Publication of MX361499B publication Critical patent/MX361499B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención, en una modalidad, proporciona un compuesto de la Fórmula I: (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, en donde las variables mostradas en la Fórmula I son como se define en la especificación.
MX2015002040A 2012-08-17 2013-08-15 Baricitinib deuterado. MX361499B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261684196P 2012-08-17 2012-08-17
US201361780661P 2013-03-13 2013-03-13
PCT/US2013/055170 WO2014028756A1 (en) 2012-08-17 2013-08-15 Deuterated baricitinib

Publications (2)

Publication Number Publication Date
MX2015002040A MX2015002040A (es) 2015-06-05
MX361499B true MX361499B (es) 2018-12-06

Family

ID=49034261

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002040A MX361499B (es) 2012-08-17 2013-08-15 Baricitinib deuterado.

Country Status (10)

Country Link
US (3) US9540367B2 (es)
EP (2) EP3492472A1 (es)
AU (1) AU2013302519B2 (es)
BR (1) BR112015003153A2 (es)
CA (1) CA2880083A1 (es)
EA (1) EA031716B1 (es)
ES (1) ES2717279T3 (es)
IN (1) IN2015DN01102A (es)
MX (1) MX361499B (es)
WO (1) WO2014028756A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2717279T3 (es) 2012-08-17 2019-06-20 Concert Pharmaceuticals Inc Baricitinib deuterada
WO2015166434A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Crystalline form of baricitinib
WO2016024231A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
HUE056329T2 (hu) 2014-08-11 2022-02-28 Acerta Pharma Bv BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
US10526350B2 (en) 2015-02-02 2020-01-07 Sun Pharmaceutical Industries Limited Process for the preparation of baricitinib and an intermediate thereof
RU2601410C1 (ru) * 2015-11-13 2016-11-10 ЗАО "Р-Фарм" {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ
RU2603959C1 (ru) * 2015-11-13 2016-12-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") ДИХЛОРАЦЕТАТ {3-[4-(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-ПИРАЗОЛ-1-ИЛ]-1-ЭТИЛСУЛЬФОНИЛ-АЗЕТИДИН-3-ИЛ}-АЦЕТОНИТРИЛА В КАЧЕСТВЕ ИНГИБИТОРА ЯНУС КИНАЗ
CN107334738B (zh) * 2016-04-28 2021-02-09 天津科伦药物研究有限公司 一种含巴瑞克替尼的药物组合物及其制备方法和用途
WO2019104214A1 (en) 2017-11-22 2019-05-31 Dauntless 2, Inc. Membrane emulsification device for microsphere creation
EP3713545A1 (en) 2017-11-22 2020-09-30 Dauntless 1, Inc. Therapeutic compound formulations
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
MA52655A (fr) 2018-03-30 2021-02-17 Incyte Corp Biomarqueurs pour maladie cutanée inflammatoire
MX2020010322A (es) 2018-03-30 2022-11-30 Incyte Corp Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
CA3132371A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
US11624751B2 (en) 2019-03-19 2023-04-11 Incyte Corporation Biomarkers for vitiligo
WO2020236950A1 (en) 2019-05-21 2020-11-26 Dauntless 1, Inc. Therapeutic microsphere formulations containing charged polymers
US20210123931A1 (en) 2019-10-10 2021-04-29 Incyte Corporation Biomarkers for graft-versus-host disease
CA3157499A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2023506118A (ja) 2019-10-16 2023-02-15 インサイト・コーポレイション 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
AU2021390533A1 (en) 2020-12-04 2023-06-29 Incyte Corporation Jak inhibitor with a vitamin d analog for treatment of skin diseases
US11918581B2 (en) 2021-01-11 2024-03-05 Incyte Corporation Combination therapy comprising JAK pathway inhibitor and rock inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6221335B1 (en) 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
BR9507200A (pt) 1994-03-25 1997-09-16 Isotechnika Inc Melhora da eficácia de drogas por deuteração
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6440710B1 (en) 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
DE60001623T2 (de) 1999-12-03 2003-12-18 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
CA2444116C (en) 2001-05-03 2009-01-20 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
US20050107420A1 (en) * 2002-05-23 2005-05-19 Boehringe Ingelheim Pharma Gmbh & Co. Kg Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
US20060094744A1 (en) 2004-09-29 2006-05-04 Maryanoff Cynthia A Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
WO2007041630A1 (en) 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7750168B2 (en) 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
MX2009002398A (es) 2006-09-05 2009-03-16 Schering Corp Combinaciones farmaceuticas para manejo de lipidos y en el tratamiento de aterosclerosis y estatosis hepatica.
US7718754B2 (en) 2007-07-30 2010-05-18 Kao Corporation Promoter for polycondensation reaction
DK2288610T3 (en) * 2008-03-11 2016-11-28 Incyte Holdings Corp Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
MX2011007750A (es) * 2009-01-23 2011-09-29 Rigel Pharmaceuticals Inc Composiciones y metodos para inhibicion de la ruta jak.
WO2012079075A1 (en) * 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
ES2717279T3 (es) 2012-08-17 2019-06-20 Concert Pharmaceuticals Inc Baricitinib deuterada

Also Published As

Publication number Publication date
US9931343B2 (en) 2018-04-03
CA2880083A1 (en) 2014-02-20
US20170189406A1 (en) 2017-07-06
BR112015003153A2 (pt) 2017-07-04
ES2717279T3 (es) 2019-06-20
AU2013302519B2 (en) 2017-11-02
US20150218158A1 (en) 2015-08-06
WO2014028756A1 (en) 2014-02-20
US20180221374A1 (en) 2018-08-09
US10842792B2 (en) 2020-11-24
EA031716B1 (ru) 2019-02-28
US9540367B2 (en) 2017-01-10
AU2013302519A1 (en) 2015-02-12
EP2885303A1 (en) 2015-06-24
MX2015002040A (es) 2015-06-05
EA201590321A1 (ru) 2015-06-30
EP3492472A1 (en) 2019-06-05
IN2015DN01102A (es) 2015-06-26
EP2885303B1 (en) 2018-12-26

Similar Documents

Publication Publication Date Title
MX2015002040A (es) Baricitinib deuterado.
MX2015001246A (es) Ibrutinib deuterado.
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
MY171055A (en) 3,5-disubstituted alkynylbenzene compound and salt thereof
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
IN2015DN00960A (es)
MX2014008729A (es) Compuestos inhibidores de metaloenzima.
MY182082A (en) Biheteroaryl compounds and uses thereof
MX2015012743A (es) Compuesto de pirazol-amida y sus usos farmaceuticos.
CR20140306A (es) Fluormetil -5,6-dihidro-4h-[1,3] oxazinas
PH12015500900A1 (en) A stabilized pemetrexed formulation
IN2012DE00621A (es)
MX2015008829A (es) Momelotinib deuterado.
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
IN2012DE00620A (es)
IN2014DN07996A (es)
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
IN2014DN10669A (es)
PH12015501146A1 (en) Hydantoin derivative
GB201020397D0 (en) Compounds
MX2015012610A (es) Pacritinib deuterizado.
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями
IN2013CH05395A (es)
UA87695U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид, що має інотропну активність

Legal Events

Date Code Title Description
FG Grant or registration